FLGT Q2 2024 Earnings — Fulgent Genetics, Inc. Revenue & Financial Results | Market Cap Arena

FLGTFulgent Genetics, Inc.

$458M

Q2 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$71M+4.7% YoY

Gross Profit

$26M37.3% margin

Operating Income

-$19M-26.6% margin

Net Income

-$9M-12.3% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+10.1%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

-$9M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$103M

Stockholders' Equity

$1.1B

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$68M	+4.7%
Gross Profit	$26M	$21M	+28.8%
Operating Income	-$19M	-$20M	+4.5%
Net Income	-$9M	-$11M	+22.4%

Revenue Segments

Laboratory Services

$71M100%

Geographic Segments

UNITED STATES

$64M82%

Non-US

$7M9%

Other Countries

$4M6%

CHINA

$2M3%